My Watchlist Items

      No Watchlist
Array ( [0] => stdClass Object ( [symbol] => ORPH [price] => 9.33 [beta] => 0.813311 [volAvg] => 846271 [mktCap] => 460537184 [lastDiv] => 0 [range] => 4.75-77.77 [changes] => -11.67 [companyName] => Orphazyme A/S [currency] => USD [cik] => 0001764791 [isin] => [cusip] => [exchange] => NMS [exchangeShortName] => NASDAQ [industry] => Biotechnology [website] => http://www.orphazyme.com [description] => Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark. [ceo] => Ms. Kim Stratton [sector] => Healthcare [country] => DK [fullTimeEmployees] => 141 [phone] => 45 39 17 82 72 [address] => Ole MaalOees Vej 3 [city] => Copenhagen [state] => [zip] => [dcfDiff] => [dcf] => 0 [image] => https://financialmodelingprep.com/image-stock/ORPH.png [ipoDate] => 2020-09-04 [defaultImage] => [isEtf] => [isActivelyTrading] => 1 ) )
Orphazyme A/S (ORPH)
   9.33   -11.67(-55.57%)
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.
TitleNamePayCurrency PayGenderYear BornTitle Since
Pres of US Orphazyme Ms. Molly Painter N/A USD female N/A N/A
Chief Medical Officer Dr. Thomas Blaettler N/A USD N/A N/A
Head of Global Communications Ms. Molly Poarch N/A USD female N/A N/A
Co-Founder & Chief Scientific Officer Dr. Thomas Kirkegaard Jensen Ph.D. N/A USD N/A N/A
Chief Financial Officer & Interim Chief Executive Officer Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBA 930400 USD male 1969 N/A
SymbolDateRatingRating Score Rating Details
ORPH 11 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 10 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 9 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 8 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 7 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 4 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 3 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 2 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 1 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 28 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 27 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 26 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 25 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 24 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 21 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 20 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 19 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 18 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 17 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 14 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 13 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 12 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 11 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 10 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 7 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 6 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 5 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 4 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 3 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 30 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 29 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 28 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 27 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 26 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 23 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 22 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 21 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 20 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 19 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 16 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 15 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 14 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 13 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 12 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 9 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 8 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 7 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 6 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 5 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 1 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
ORPH 31 March, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
ORPH 30 March, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
ORPH 29 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 26 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 25 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 24 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 23 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 22 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 19 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 18 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 17 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 16 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 15 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 12 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 11 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 10 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 9 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 8 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 5 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 4 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
ORPH 3 March, 2021 B- 3 Rating DCF: (Strong Buy)
Rating ROE: (Strong Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Neutral)
HolderSharesDate ReportedChange
MILLENNIUM MANAGEMENT LLC 133536 31 December, 2020 -64020
CAAS CAPITAL MANAGEMENT LP 25000 31 December, 2020 0
BANK OF AMERICA CORP /DE/ 6301 31 December, 2020 -522690
ADVISOR GROUP HOLDINGS, INC. 5680 31 December, 2020 5680
UBS GROUP AG 2327 31 December, 2020 2327
SymbolDatePeriodDownload XLSX File
ORPH 2021 FY Download XLSX File
ORPH 2020 FY Download XLSX File
ORPH 2021 Q1 Download XLSX File
ORPH 2020 Q4 Download XLSX File

Charts

Company Profile

Company Name Orphazyme A/S
Symbol ORPH
Currency USD
Price 9.33
Exchange Name NMS (NASDAQ)
Industry Biotechnology
CEO Ms. Kim Stratton
Sector Healthcare
Country DK
Full Time Employees 141
Phone 45 39 17 82 72
Address Ole MaalOees Vej 3
City Copenhagen
>